Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

New therapeutic strategies targeting D1-type dopamine receptors for neuropsychiatric disease.

Kim YC, Alberico SL, Emmons E, Narayanan NS.

Front Biol (Beijing). 2015 Jun;10(3):230-238. doi: 10.1007/s11515-015-1360-4. Epub 2015 May 13.

2.

COMT and DRD2/ANKK-1 gene-gene interaction account for resetting of gamma neural oscillations to auditory stimulus-driven attention.

Garcia-Garcia M, Via M, Zarnowiec K, SanMiguel I, Escera C, Clemente IC.

PLoS One. 2017 Feb 21;12(2):e0172362. doi: 10.1371/journal.pone.0172362. eCollection 2017.

3.

Dopamine D2 receptor availability is linked to hippocampal-caudate functional connectivity and episodic memory.

Nyberg L, Karalija N, Salami A, Andersson M, Wåhlin A, Kaboovand N, Köhncke Y, Axelsson J, Rieckmann A, Papenberg G, Garrett DD, Riklund K, Lövdén M, Lindenberger U, Bäckman L.

Proc Natl Acad Sci U S A. 2016 Jul 12;113(28):7918-23. doi: 10.1073/pnas.1606309113. Epub 2016 Jun 23.

4.

The relationship between dopamine receptor D1 and cognitive performance.

Tsang J, Fullard JF, Giakoumaki SG, Katsel P, Katsel P, Karagiorga VE, Greenwood TA, Braff DL, Siever LJ, Bitsios P, Haroutunian V, Roussos P.

NPJ Schizophr. 2015 Mar 4;1:14002. doi: 10.1038/npjschz.2014.2. eCollection 2015. Erratum in: NPJ Schizophr. 2015;1:15018.

5.

Degeneration of Dopaminergic Neurons Due to Metabolic Alterations and Parkinson's Disease.

Song J, Kim J.

Front Aging Neurosci. 2016 Mar 30;8:65. doi: 10.3389/fnagi.2016.00065. eCollection 2016. Review.

6.

COMT val158met polymorphism and molecular alterations in the human dorsolateral prefrontal cortex: Differences in controls and in schizophrenia.

Shukla AA, Jha M, Birchfield T, Mukherjee S, Gleason K, Abdisalaam S, Asaithamby A, Adams-Huet B, Tamminga CA, Ghose S.

Schizophr Res. 2016 May;173(1-2):94-100. doi: 10.1016/j.schres.2016.03.019. Epub 2016 Mar 24.

7.

Novel Dopamine Therapeutics for Cognitive Deficits in Schizophrenia.

Arnsten AF, Girgis RR, Gray DL, Mailman RB.

Biol Psychiatry. 2017 Jan 1;81(1):67-77. doi: 10.1016/j.biopsych.2015.12.028. Epub 2016 Jan 18. Review.

PMID:
26946382
8.

An investigation into aripiprazole's partial D₂ agonist effects within the dorsolateral prefrontal cortex during working memory in healthy volunteers.

Murphy A, Dursun S, McKie S, Elliott R, Deakin JF.

Psychopharmacology (Berl). 2016 Apr;233(8):1415-26. doi: 10.1007/s00213-016-4234-9. Epub 2016 Feb 22.

9.

Norepinephrine versus dopamine and their interaction in modulating synaptic function in the prefrontal cortex.

Xing B, Li YC, Gao WJ.

Brain Res. 2016 Jun 15;1641(Pt B):217-33. doi: 10.1016/j.brainres.2016.01.005. Epub 2016 Jan 11. Review.

10.

Stochastic Mesocortical Dynamics and Robustness of Working Memory during Delay-Period.

Reneaux M, Gupta R, Karmeshu.

PLoS One. 2015 Dec 4;10(12):e0144378. doi: 10.1371/journal.pone.0144378. eCollection 2015.

11.

Phospholipase C-β1 Hypofunction in the Pathogenesis of Schizophrenia.

Kim SW, Cho T, Lee S.

Front Psychiatry. 2015 Nov 17;6:159. doi: 10.3389/fpsyt.2015.00159. eCollection 2015. Review.

12.

Development and function of the midbrain dopamine system: what we know and what we need to.

Bissonette GB, Roesch MR.

Genes Brain Behav. 2016 Jan;15(1):62-73. doi: 10.1111/gbb.12257. Epub 2015 Nov 8. Review.

13.

Growth Hormone Secretagogue Receptor Dimers: A New Pharmacological Target(1,2,3).

Wellman M, Abizaid A.

eNeuro. 2015 Apr 24;2(2). pii: ENEURO.0053-14.2015. doi: 10.1523/ENEURO.0053-14.2015. eCollection 2015 Mar-Apr. Review.

14.

The effect of modafinil on the rat dopamine transporter and dopamine receptors D1-D3 paralleling cognitive enhancement in the radial arm maze.

Karabacak Y, Sase S, Aher YD, Sase A, Saroja SR, Cicvaric A, Höger H, Berger M, Bakulev V, Sitte HH, Leban J, Monje FJ, Lubec G.

Front Behav Neurosci. 2015 Aug 19;9:215. doi: 10.3389/fnbeh.2015.00215. eCollection 2015.

15.

Neuroenhancement of Exposure Therapy in Anxiety Disorders.

Hofmann SG, Mundy EA, Curtiss J.

AIMS Neurosci. 2015;2(3):123-138.

16.

Amphetamine Exerts Dose-Dependent Changes in Prefrontal Cortex Attractor Dynamics during Working Memory.

Lapish CC, Balaguer-Ballester E, Seamans JK, Phillips AG, Durstewitz D.

J Neurosci. 2015 Jul 15;35(28):10172-87. doi: 10.1523/JNEUROSCI.2421-14.2015.

17.

Dopamine's Actions in Primate Prefrontal Cortex: Challenges for Treating Cognitive Disorders.

Arnsten AF, Wang M, Paspalas CD.

Pharmacol Rev. 2015 Jul;67(3):681-96. doi: 10.1124/pr.115.010512. Review.

18.

Deficits in prefrontal cortical and extrastriatal dopamine release in schizophrenia: a positron emission tomographic functional magnetic resonance imaging study.

Slifstein M, van de Giessen E, Van Snellenberg J, Thompson JL, Narendran R, Gil R, Hackett E, Girgis R, Ojeil N, Moore H, D'Souza D, Malison RT, Huang Y, Lim K, Nabulsi N, Carson RE, Lieberman JA, Abi-Dargham A.

JAMA Psychiatry. 2015 Apr;72(4):316-24. doi: 10.1001/jamapsychiatry.2014.2414.

19.

D1-dependent 4 Hz oscillations and ramping activity in rodent medial frontal cortex during interval timing.

Parker KL, Chen KH, Kingyon JR, Cavanagh JF, Narayanan NS.

J Neurosci. 2014 Dec 10;34(50):16774-83. doi: 10.1523/JNEUROSCI.2772-14.2014.

20.

Striatal and extrastriatal dopamine transporter levels relate to cognition in Lewy body diseases: an (11)C altropane positron emission tomography study.

Marquie M, Locascio JJ, Rentz DM, Becker JA, Hedden T, Johnson KA, Growdon JH, Gomperts SN.

Alzheimers Res Ther. 2014 Aug 27;6(5-8):52. doi: 10.1186/s13195-014-0052-7. eCollection 2014.

Supplemental Content

Support Center